Dafna Capital Management LLC Adc Therapeutics Sa Transaction History
Dafna Capital Management LLC
- $368 Million
- Q3 2025
A detailed history of Dafna Capital Management LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Dafna Capital Management LLC holds 122,081 shares of ADCT stock, worth $483,440. This represents 0.13% of its overall portfolio holdings.
Number of Shares
122,081
Previous 122,081
-0.0%
Holding current value
$483,440
Previous $327,000
49.24%
% of portfolio
0.13%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding ADCT
# of Institutions
108Shares Held
67.3MCall Options Held
39.8KPut Options Held
68.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Morgan Stanley New York, NY3.67MShares$14.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...